Abstract
Small-cell lung cancer (SCLC) is a neuroendocrine tumor that represents about 12–20% of all lung cancers. Most of the SCLC patients present with extensive-stage (ES) disease. Primary therapy for ES-SCLC is 4–6 cycles of platinum-based chemotherapy (CT) followed by prophylactic cranial irradiation (PCI) in selected cases. Although the response rate to CT is approximately 60–70%, median survival times are very limited. The main problem of ES-SCLC patients after CT is intra-thoracic tumor recurrence since 75% of the patients had persisting intra-thoracic disease after CT, and approximately 90% of the patients had intra-thoracic progressive disease within the first year after diagnosis. Such high rate of intra-thoracic disease progression explains the need of local treatment in selected patients. There are three randomized studies and two meta-analyses evaluating the role of thoracic radiotherapy (TRT) in patients with ES-SCLC who responded to CT. Two of the randomized trials and one of the meta-analyses showed survival benefit of TRT. According to the results of relevant studies, the patients who responded to CT and have intra-thoracic residual disease after CT, who had limited metastatic sites (≤ 2), and who have good performance status and limited weight loss have more benefit from TRT. We need novel studies evaluating the optimal dose fractionation schedules, optimal timing of RT, impact of time interval between RT and CT, immunotherapy and RT combinations, and number of CT cycles.
Similar content being viewed by others
References
van Meerbeeck JP, Fennell DA, De Ruysscher DK (2011) Small-cell lung cancer. Lancet 378:1741–1755
Houston KA, Henly SJ, Li J, White MC, Richards TB (2014) Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009. Lung Cancer 86:22–28
Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, ESMO Guidelines Working Group (2013) Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi99–v105
Byers LA, Rudin CM (2015) Small cell lung cancer: where do we go from here? Cancer 121:664–672
Zelen M (1973) Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 4:31/42
Stahel RA, Ginsberg R, Havemann K et al (1989) Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 5:119–126
American Joint Committee on Cancer (2010) AJCC cancer staging handbook, 7th edn. Springer, New York, p 299323
NCCN clinical practice guidelines in oncology: small cell lung cancer. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Version 1.2019 — October 10, 2018. Accessed: March 19, 2019
Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM (2013) Executive summary: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):7S–37S
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220–2229
Jeremic B, Shibamoto Y, Nikolic N et al (1999) Role of radiation therapy in the combined-modality treatment of patients with extensive stage small-cell lung cancer: a randomized study. J Clin Oncol 17:2092–2099
Slotman BJ, van Tinteren H, Praag JO et al (2015) Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomized controlled trial. Lancet 385:36–42
Palma DA, Warner A, Louie AV, Senan S, Slotman B, Rodrigues GB (2016) Thoracic radiotherapy for extensive stage small-cell lung cancer: a meta-analysis. Clin Lung Cancer 17(4):239–244
Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF et al (1994) Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol 12:2022–2034
Bunn PA Jr, Cohen MH, Ihde DC, Fossieck BE Jr, Matthews MJ, Minna JD (1977) Advances in small cell bronchogenic carcinoma: a commentary. Cancer Treat Rep 61:333–342
Beck LK, Kane MA, Bunn PA Jr (1988) Innovative and future approaches to small cell lung cancer treatment. Semin Oncol 15:300–314
Slotman BJ, FaivreFinn C, Kramer G et al (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357:664–672
Jeremic B, Gomez-Caamano A, Dubinsky P, Cihoric N, Casas F, Filipovic N (2017) Radiation therapy in extensive stage small cell lung cancer. Front Oncol 7:169
Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE et al (2017) Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extra-cranial irradiation for extensive disease small cell lung cancer (ED-SCLC): NRG oncology RTOG 0937. J Thorac Oncol 12(10):1561–1570
Rathod S, Jeremic B, Dubey A, Giuliani M, Bashir B, Chowdhury A, Liang Y, Pereira S, Agarwal J, Koul R (2019) Role of thoracic consolidation radiation in extensive stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Eur J Cancer 110:110–119
Slotman BJ, Faivre-Finn C, van Tinteren H, Keijser A, Praag J, Knegjens J, Hatton M et al (2017) Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the Phase III CREST trial. Lung Cancer 108:150–153
Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, Sharouni El SY, Hatton M et al (2015) Radiotherapy for extensive stage small-cell lung cancer – authors’ reply. Lancet 385:1292–1293
Slotman BJ, van Tinteren H (2015) Which patients with extensive stage small-cell lung cancer should and should not receive thoracic radiotherapy. Transl Lung Cancer Res 4:292–294
Xu LM, Cheng C, Kang M et al (2017) Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer. Sci Rep 7(1):9255
Li-Ming X, Zhao LJ, Simone CB 2nd, Cheng C, Kang M, Wang X, Gong LL, Pang QS, Wang J, Yuan ZY, Wang P (2017) Receipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancer. Radiother Oncol 125(2):331–337
Hasan S, Renz P, Turrisi A, Colonias A, Finley G, Wegner RE (2018) Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): a National Cancer Database (NCDB) propensity-matched analysis. Lung Cancer 124:283–290
Singer L, Yom SS (2015) Consolidative radiation therapy for extensive stage small cell lung cancer. Transl Lung Cancer Res 4(3):211–214
Kalemkerian GP, Loo BW, Akerley W et al. NCCN guidelines version 1.2019 Panel Members Small Cell Lung Cancer Charles Florsheim Patient Advocate. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed April 21, 2019
Mitin T, Jain A, Degnin C, Chen Y, Henderson M, Thomas CR Jr (2016) Current patterns of care for patients with extensive stage small cell lung cancer: Survey of US radiation oncologists on their recommendations regarding thoracic consolidation radiotherapy. Lung Cancer 100:85–89
De Ruysscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, Lutgens L, Hochstenbag M, Boersma L, Wouters B, Lammering G, Vansteenkiste J (2006) Lambin P (2006) Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24(7):1057–1063
Overgaard J, Hansen HS, Specht L et al (2003) Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362:933–940
Bernier J, Bentzen SM (2003) Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 39:560–571
Bentzen SM (2003) Repopulation in radiation oncology: perspectives of clinical research. Int J Radiat Biol 79:581–585
Davis AJ, Tannock IF (2000) Repopulation of tumor cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 1:86–93
Jackman DM, Johnson BE (2005) Small-cell lung cancer. Lancet 366(9494):1385–1396
De Ruysscher D, Vansteenkiste J (2000) Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects. Radiother Oncol 55:1–9
Pijls-Johannesma MCG, De Ruysscher DKM, Rutten I et al (2005) Early versus late chest radiotherapy for limited stage small cell lung cancer. In: The Cochrane Library (issue 1). Wiley, Chichester, p CD004700
Fried DB, Morris DE, Poole C et al (2004) Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22:4837–4845
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This article does not contain any studies with human participants or animals performed by any of the authors.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yavas, G., Yavas, C. Thoracic radiotherapy for extensive-stage small-cell lung cancer: what is the optimal dose and timing?. J Radiat Oncol 8, 251–258 (2019). https://doi.org/10.1007/s13566-019-00406-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13566-019-00406-x